Genetics

High Immune Gene Expression Linked to Better Prognosis in TNBC

High Immune Gene Expression Linked to Better Prognosis in TNBC

By

Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.

Men With Genetic Risk of CRC May Lower Risk Via Healthy Lifestyle

Men With Genetic Risk of CRC May Lower Risk Via Healthy Lifestyle

Adopting healthy lifestyle can cut 25-year risk for the disease from 29 to 13 percent.

New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect

By

A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

By

Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

By

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

Cancer Cell Lines Can Predict Treatment Response, Improve Personalized Therapy

By

Patient-derived cancer cell lines contain most of the genetic changes found in patients' tumors and could be used to determine tumor response to treatment, increasing the success rate of new personalized therapies for cancer.

Hybrid Immune Cells Have Antitumor Effects in Early Stage Lung Cancer

Hybrid Immune Cells Have Antitumor Effects in Early Stage Lung Cancer

By

A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.

Identifying Smaller ctDNA Fragments Improves Sensitivity of Liquid Biopsy

Identifying Smaller ctDNA Fragments Improves Sensitivity of Liquid Biopsy

By

Circulating tumor DNA (ctDNA) has shorter fragment sizes than DNA fragments from healthy cells that have died, and this may increase the clinical utility of liquid biopsies.

Blood Biomarker Is Predictive of Risk for Colon Cancer Recurrence

Blood Biomarker Is Predictive of Risk for Colon Cancer Recurrence

By

Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.

Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma

Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma

By

Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.

Rare Mutations in Immune-Related Genes Linked to Multiple Simultaneous Colorectal Cancer Tumors

By

Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.

Epigenetic Regulator of Tumorigenesis Suggests New Strategies Against Breast Cancer

By

The protein CBX8 uses a previously unknown mechanism to promote the origin of breast tumors, or tumorigenesis, in the most lethal forms of breast cancer, according to new research.

Genetic Picture of Colorectal Cancer Expanded

Genetic Picture of Colorectal Cancer Expanded

Researchers say it's likely that all the major genetic mutations related to colorectal cancer have been discovered.

Genetic Subtypes of HLA Are Linked to Increased Overall Risk of Ovarian Cancer

By

Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.

Gene Expression Pattern in Surrounding Normal Tissue Linked to Breast Cancer Prognosis

By

A gene expression pattern in the noncancerous tissues surrounding estrogen receptor-positive breast cancer is associated with lower 10-year survival rates.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

By

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Gene Activity Predicts Patient Response to Inhibitor Treatment for Stomach Cancer

By

Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

By

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

By

The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Discovery might eventually lead to better treatment for glioblastoma multiforme

Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer

By

Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

By

The Bim protein might predict which patients could be successfully treated with immunotherapy for metastatic melanoma.

No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women

By

Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

By

Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.

New Mechanism to Target RAS Genes Identified

New Mechanism to Target RAS Genes Identified

By

A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.

Research Reveals Evolution of TRK-fusion Inhibitor Resistance in Cancer

By

Researchers have pinpointed the evolutionary process cancer cells use to resist the drug LOXO-101.

Tumor Regression Achieved With LOXO-101 in Phase 1 Study

By

Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

By

Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.

Osimertinib Proven Effective as First-line Therapy for EGFR-positive NSCLC

By

Osimertinib effectively treats EGFR-mutated non-small cell lung cancer that has the T790M mutation, according to recent study findings.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs